Ho, Alan L <br/><br/>
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.  [electronic resource] 

 -  PloS one  2012 
 - e40439 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0040439  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptor Proteins, Signal Transducing--metabolism<br/>Animals<br/>Apoptosis--drug effects<br/>Benzimidazoles--pharmacology<br/>Cell Cycle Proteins<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>GTP-Binding Protein alpha Subunits--genetics<br/>GTP-Binding Protein alpha Subunits, Gq-G11<br/>Genotype<br/>Humans<br/>Mechanistic Target of Rapamycin Complex 2<br/>Melanoma--drug therapy<br/>Mice<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Models, Biological<br/>Morpholines--pharmacology<br/>Multiprotein Complexes--metabolism<br/>Mutation--genetics<br/>Myeloid Cell Leukemia Sequence 1 Protein<br/>Phosphoproteins--metabolism<br/>Phosphorylation--drug effects<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Receptor, IGF Type 1--metabolism<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Uveal Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays<br/>Uveal Melanoma